Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 1421

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 9A
Chunk 1421
---
 For the 

    Year Ended  
    Year Ended 

    December 31,  2024  
    December 31,  2023 
  
    Cash flows from operating activities: 

    Net (loss)/income 
    $(167,306) 
    $632,536 
  
    Adjustments to reconcile net (loss)/ income to net cash used in operating activities: 

    Income from Trust 
     (1,578,042) 
     (3,843,271)
  
    Changes in current assets and liabilities: 

    Prepaid Expenses 
     4,976  
     83,113 
  
    Accounts payable and accrued expenses 
     890,833  
     2,457,940 
  
    Accrued interest expense -related party 
     56,534  
     18,021 
  
    Accrued interest expense - others 
     39,709  
     18,878 
  
    Net cash used in operating activities 
     (753,296) 
     (632,783)

    Cash Flows from Investing Activities: 

    Investment held in Trust Account 
     -  
     (825,000)
  
    Cash withdrawn from Trust Account in connection with redemption 
     43,425,328  
     40,536,908 
  
    Net cash provided by investing activities 
     43,425,328  
     39,711,908 

    Cash flows from financing activities: 

    Proceeds from issuance of promissory note to related party 
     565,700  
     842,500 
  
    Redemption of ordinary shares 
     (43,425,328) 
     (40,536,908)
  
    Net cash used in financing activities 
     (42,859,628) 
     (39,694,408)

    Net change in cash 
     (187,596) 
     (615,283)

    Cash, beginning of the year 
     204,464  
     819,747 
  
    Cash, end of the year 
    $16,868  
    $204,464 

    Supplemental disclosure of noncash investing and financing activities 

    Increase in investment held in Trust Account through issuance of promissory note 
    $390,329  
    $975